Patents by Inventor Charlotte M. McGuinness
Charlotte M. McGuinness has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040219213Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.Type: ApplicationFiled: January 16, 2004Publication date: November 4, 2004Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Charlotte M. McGuinness, Edward M. Rudnic
-
Patent number: 6692767Abstract: Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) a therapeutic agent which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting point of about 40 to about 100° C., and is most preferably glyceryl behenate. The surfactant is preferably a polyglycolyzed glyceride, polyoxyethylene sorbate, ethylene or propylene block copolymer or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate.Type: GrantFiled: September 18, 1998Date of Patent: February 17, 2004Assignee: Shire Laboratories Inc.Inventors: Beth A. Burnside, Charlotte M. McGuinness, Edward M. Rudnic, Richard A. Couch, Xiaodi Guo, Alexander K. Tustian
-
Patent number: 6605300Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.Type: GrantFiled: July 19, 2001Date of Patent: August 12, 2003Assignee: Shire Laboratories, Inc.Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Charlotte M. McGuinness, Edward M. Rudnic
-
Publication number: 20030124188Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.Type: ApplicationFiled: June 14, 2002Publication date: July 3, 2003Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Charlotte M. McGuinness, Edward M. Rudnic
-
Publication number: 20010055613Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.Type: ApplicationFiled: October 21, 1998Publication date: December 27, 2001Inventors: BETH A. BURNSIDE, XIAODI GUO, KIMBERLY FISKE, RICHARD A. COUCH, RONG-KUN CHANG, DONALD J. TREACY, CHARLOTTE M. MCGUINNESS, EDWARD M. RUDNIC
-
Publication number: 20010006650Abstract: Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) of a therapeutic agent which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting point of about 40 to about 100° C., and is most preferably glyceryl behenate. The surfactant is preferably a polyglycolyzed glyceride, polyoxyethylene sorbate, ethylene or propylene block copolymer or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate.Type: ApplicationFiled: September 18, 1998Publication date: July 5, 2001Inventors: BETH A. BURNSIDE, CHARLOTTE M. MCGUINNESS, EDWARD M. RUDNIC, RICHARD A. COUCH, XIAODI GUO, ALEXANDER K. TUSTIAN
-
Patent number: 5948407Abstract: Disclosed is a method for reducing an immune response to a parenterally administered non-autologous antigen in an individual who is immunologically responsive thereto by mucosally administering to the individual an amount of the antigen effective to reduce any immune response to parenteral administration of said antigen. The antigen can be a polypeptide such as a hormone, like insulin, which supplements a metabolic deficiency in the recipient of a polypeptide intended to serve the same function. The polypeptide can also be one which supplements a deficiency in the production of a physiologically important polypeptide, such as a hematologic regulatory factor. The hematologic regulatory factor can enhance or inhibit thrombogenesis or platelet deposition. Also, the antigen can be a tissue or cell preparation, such as of allogeneic or xenogeneic tissue or cells.Type: GrantFiled: March 18, 1998Date of Patent: September 7, 1999Assignee: Shire Laboratories Inc.Inventors: Charlotte M. McGuinness, Beth A. Burnside, Edward M. Rudnik
-
Patent number: 5897876Abstract: A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with pharmaceutical agent is incorporated into a pharmaceutical carrier suitable for oral delivery.Type: GrantFiled: June 20, 1997Date of Patent: April 27, 1999Assignee: Shire Laboratories Inc.Inventors: Edward M. Rudnic, John A. McCarty, George W. Belendiuk, deceased, Beth A. Burnside, Charlotte M. McGuinness, Krystyna Belendiuk
-
Patent number: 5883103Abstract: A pharmaceutical preparation for oral acyclovir delivery comprising a stable, hydrophobic emulsion comprising continuous phase of a hydrophobic material selected from the group consisting of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with acyclovir is incorporated into a pharmaceutical carrier suitable for oral delivery.Type: GrantFiled: June 7, 1995Date of Patent: March 16, 1999Assignee: Shire Laboratories Inc.Inventors: Beth A. Burnside, Carol E. Mattes, Charlotte M. McGuinness, Edward M. Rudnic, George W. Belendiuk
-
Patent number: 5824638Abstract: A pharmaceutical preparation for oral insulin delivery comprising a stable, hydrophobic emulsion comprising continuous phase of a hydrophobic material selected from the group consisting of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with insulin is incorporated into a pharmaceutical carrier suitable for oral delivery.Type: GrantFiled: May 22, 1995Date of Patent: October 20, 1998Assignee: Shire Laboratories, Inc.Inventors: Beth A. Burnside, Carol E. Mattes, Charlotte M. McGuinness, Edward M. Rudnic, George W. Belendiuk, deceased
-
Patent number: RE41148Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.Type: GrantFiled: October 20, 1999Date of Patent: February 23, 2010Assignee: Shire Laboratories, Inc.Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Edward M. Rudnic, Charlotte M. McGuinness